321550 — TiumBio Share News
0.000.00%
Last trade - 00:00- KR₩122bn
- KR₩129bn
- KR₩12bn
Brief: TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab
Brief: TiumBio Submits CTA For Phase 1b Clinical Trial Of TU7710
Brief: Tiumbio To Initiate Phase 2 Trial Of Tu2218 For Cancer
Brief: Tiumbio And Hansoh Pharma Announce Clinical Trial Approval Of 'HS-10518/TU2670' From NMPA In China
Brief: Oncodesign And Tiumbio Sign Collaboration Agreement For Research And Development Of Fibrosis Drug Candidates